Trillium Therapeutics Culture d’entreprise

Dr. Penka Petrova, Ph.D. has been the Chief Development Officer of Trillium Therapeutics Inc. since May 29, 2015. Dr. Petrova served as a Vice President of Drug Development at Trillium Therapeutics Inc. since April 9, 2013. Dr. Petrova served as the Head of Biology Group and Director of Drug Development of Trillium Therapeutics Inc. She was responsible for managing Trillium Therapeutics' formal drug development efforts, including all outsourced activities to CMOs and CROs. She oversees all the Trillium Therapeutics' in vivo studies. Dr. Petrova joined TTI from Prescient Neuropharma in 2003, where she held a Research Scientist position and was involved in identifying and characterizing novel proteins involved in neuroprotection. She received her Ph.D. in Microbiology from Saarland University in Saarbruecken, Germany, where she also conducted her post doctoral studies.

Dr. Robert Uger, Ph.D., as known as Bob, has been the Chief Scientific Officer at Trillium Therapeutics Inc., since April 9, 2013. Dr. Uger served as Vice President of Research & Development at Trillium Therapeutics Inc. Dr. Uger is responsible for developing and implementing the scientific direction of TTI and oversees both internal product development and external research discovery programs. He joined TTI from Aventis Pasteur where was a Senior Research Scientist involved in cancer vaccine research. He received his Ph.D. in Immunology from the University of Toronto.